Menu Page-General Template
2006 Presentations: Biographical Sketches
Mark Avigan obtained his B.Sc. (1972) and M.D. C.M. degrees (1977) from McGill University in Montreal, Canada. He completed residency training in Internal Medicine at the VA Medical Center/Georgetown University in Washington DC. Subsequently, he served as Chief Medical Resident and completed a clinical GI/Hepatology/Nutrition fellowship. Dr. Avigan served as a staff fellow in the Liver Unit of the National Institute of Arthritis Diabetes, and Digestive and Kidney Diseases in Bethesda Maryland and later moved to NCI where he pursued studies in molecular and cellular mechanisms governing the dysfunctional expression of oncogenes during carcinogenesis.
In 1990 he joined the faculty at the School of Medicine at Georgetown University. As an assistant and later associate professor he attended patients on the GI/Liver service at the Georgetown University Medical Center and served as a mentor in the GI clinical fellowship program. In addition, he was the principal investigator of NIH funded R-29 and R0-1 grants that supported studies to elucidate transcriptional and post-transcriptional growth regulation by cytokines.
After joining the Center for Drug Evaluation of the Food and Drug Administration in 1999 as a Medical Officer in the Division of Gastrointestinal and Coagulation Drug Products he became a Senior Medical Reviewer in 2002. He is currently serving as Director of the Division of Drug Risk Evaluation in the Office of Drug Safety.
Herbert L. Bonkovsky, M.D.
Herbert L. Bonkovsky, M.D., Professor of Medicine and Molecular, Microbial, and Structural Biology, and Director of The Liver-Biliary-Pancreatic Center, at The University of CT Health Center, is known nationally and internationally as a clinical hepatologist, teacher, mentor, and clinical investigator. Dr. Bonkovsky is a graduate of Earlham College and Case Western Reserve University School of Medicine. His Post-graduate training was at Duke University, Case Western Reserve University School of Medicine, The U.S. National Institutes of Health, Dartmouth Medical School, and Yale University. Dr. Bonkovsky has served as Director of the Division of Digestive Disease and Nutrition at the University of Massachusetts Medical School and as Director of the Office of Clinical Research and the General Clinical Research Center at the University of Connecticut Health Center. His currently funded research is in porphyria and heme metabolism, chronic viral hepatitis, and the drug-induced liver injury. For the past twelve consecutive years, Dr. Bonkovsky has been selected by his peers as one of America?s Top Doctors.
Back to 2006 PresentationsDaniel K. Burns, Ph.D.
Senior Vice President, Therapeutic Area Teams, GlaxoSmithKline
Dan was educated at Indiana University receiving a Bachelor of Science in 1977, a Masters degree in 1979 and a Ph.D. in Cellular, Molecular and Developmental Biology in 1984. He pursued post doctoral research at Hoffmann-La Roche in Nutley New Jersey, utilizing molecular biology techniques to investigate the structure function relationship of proteins. He subsequently assumed a staff scientist position at Hoffmann La Roche and established a laboratory group investigating the molecular basis of the inflammatory response. In 1993 Dan joined Glaxo to establish a molecular biology laboratory to investigate the molecular and genetic basis of insulin resistance and type II diabetes. Following the merger of Glaxo and Burroughs Wellcome he assumed leadership responsibilities for the Genetics Research Initiative in Diabetes, participated in the development of the Genetics Directorate and served as the Head, Department for Human Genetics. As head of GSK?s Discovery Genetics, he directed the activities of 140 scientists in the U.S. and U.K. aimed at identifying disease susceptibility genes, determining the function of genes and understanding the role of genetics in the safety and efficacy of medicines. He now serves as Senior VP of the GR-Therapeutic Area Teams (TATs), which are responsible for interfacing with all of R&D and determining how genetics and genomics can best support drug discovery and development and optimize the delivery of safe and effective medicines to the people who need them.
Back to 2006 PresentationsNaga Chalasani was educated at the Andhra Loyola College in India (biology 1979-81) and the Kakatiya Medical College (MB, BS 1988), after which he served as an internal medical resident at Emory University in Atlanta (1991-4). He followed with a fellowship in gastroenterology and hepatology at Emory (1994-7). He joined Indiana University Hospital in Indianapolis (IN) in 1997, where he currently serves as an associate professor of medicine in the Divisions of Gastroenterology/Hepatology and the Division of Clinical Pharmacology. He was elected to Alpha Omega Alpha, 1993; received the Dupont Young Investigator?s Award 1993; and the IUSM Young Investigator of the Year, 2002. He is the PI for the NIDDK-funded DILIN Clinical Center and NASH CRN Clinical Center at Indiana University.
Back to 2006 PresentationsDr. Davern attended the College of the Holy Cross, received his medical degree from Columbia University College of Physicians and Surgeons, and subsequently trained in Internal Medicine at Beth Israel Hospital, Boston. Dr. Davern completed his gastroenterology/ hepatology training at the University of California San Francisco and has been on the faculty since 1997. He is currently an Associate Professor of Medicine. Dr. Davern?s research interests include drug induced liver disease, acute liver failure, and hepatic gene therapy. He is a principal investigator at one of the 5 clinical sites comprising the Drug Induced Liver Injury Network (DILIN), and is also a site PI in the US Acute Liver Failure Study Group.
Back to 2006 PresentationsYvonne P Dragan, PhD
Director, Division of Systems Toxicology
National Center for Toxicology Research, FDA, Jefferson AR
Dr Yvonne Dragan received her Ph.D. in Pharmacology and Toxicology from the Medical College of Virginia in 1988. She performed postdoctoral work in the Department of Oncology at the University of Wisconsin in Madison at the McArdle Laboratory for Cancer Research followed by several research faculty appointments from 1988 until 1998. She was a member of the School of Public Health faculty at the Ohio State University from 1998-2001. Dr. Dragan is currently the Director of the Division of Systems Toxicology at the FDA?s National Center for Toxicological Research in Jefferson, Arkansas. She has worked at the NCTR since 2002 as the Director of the Program in Hepatotoxicity and is an adjunct Associate Professor in Pharmacology and Toxicology at the University of Arkansas for Medical Sciences. She has been an active member of the Society of Toxicology (SOT) since 1988. Dr. Dragan has served as President of the Ohio Valley Regional Chapter (2001), Member (1999-2001) and Chair of the Continuing Education Committee (2001), and President of the Carcinogenesis Specialty Section (2001) of the Society of Toxicology. She is currently an elected member of the SOT Council with Liaison roles to the Education and Continuing Education Committee. She additionally holds memberships in the American Association for Cancer Research, Society of Toxicologic Pathology, American Society for Pharmacology and Experimental Therapeutics and the American Association for the Study of Liver Disease. Dr Dragan has over 70 peer reviewed papers and more than a dozen book chapters. Dr Dragan is a member of the Interdisciplinary Pharmacogenomics Review Group and is an active member of the Voluntary Genomics Data Submissions Review Group at FDA.
Back to 2006 PresentationsJames Freston, M.D., Ph.D.
University of Connecticut School of Medicine
James Freston is Boehringer Ingelheim Chair of Clinical Pharmacology and Professor of Medicine Emeritus at The University of Connecticut School of Medicine in Farmington, Connecticut. He was Chief of the Divisions of Gastroenterology and Hepatology and Clinical Pharmacology at the University of Utah before his appointment as Professor and Chair of the Department of Medicine at the University of Connecticut, a position held for 17 years before becoming Director of Clinical Research.
He trained in gastroenterology and clinical pharmacology at the University of Utah and in hepatology for two years under Sheila Sherlock at the Royal Free Hospital in London. Throughout his career, he has focused on the effects of drugs on digestive diseases, with an emphasis on toxicity and safety, and on the effects of digestive diseases on drug disposition. He served twice on FDA GI Drugs Advisory Committees. His recent work has focused on a semiquantitative assessment of the relative consequences of the clinical, pathological and biochemical manifestations of DILI. He is a DILIN co-investigator at the University of Connecticut and serves on the DILIN Causality Committee.
He is Chair of the Foundation for Digestive Health and Nutrition and Past President of the American Gastroenterological Association. He received his M.D. degree from the University of Utah and his Ph.D. degree from the University of London.
Dr. Lee was educated at Amherst College and received his medical degree from Columbia University College of Physicians and Surgeons, AOA, completing his training in Internal Medicine at the Presbyterian Hospital, New York City (Columbia-Presbyterian Medical Center). He served as Honorary Registrar and Research Fellow to Dr. Roger Williams at the Liver Unit, Kings College Hospital, London from 1973-74, then was on the faculty of Columbia-Presbyterian and later served as Chief of Gastroenterology at the MUSC, Charleston, SC. Since 1990 he has been Professor of Internal Medicine at UT Southwestern Medical Center at Dallas, and holder of the Meredith Mosle Chair in Liver Disease and Director, Clinical Center for Liver Disease. UT Southwestern Medical Center at Dallas.
Dr. Lee is Principal Investigator for the NIH-sponsored Acute Liver Failure Study Group comprising 24 adult and 24 pediatric sites. In addition, he is Principal Investigator for one of the 10 sites participating in the NIH HALT-C study, a long-term treatment program for patients who are non-responders to interferon therapy. His group currently is conducting more than 10 trials of new agents for the treatment of viral hepatitis and conducts basic research in hepatitis B and C.
Back to 2006 PresentationsRobert N. McBurney, PhD
Senior Vice President, Research & Development and Chief Scientific Office, BG Medicine, Inc.
Dr. McBurney joined BG Medicine in 2003 following his position as Founder, President and CEO of Differential Proteomics, Inc., an emerging proteomics company. From 2000-2001, he held the position of President of CeNeS Pharmaceuticals, Inc., and from 1990-2000 was Chief Scientific Officer and then President of Cambridge NeuroScience, Inc. (CNSI). While at CNSI, Dr. McBurney was responsible for multiple drug discovery and development projects focused on treating stroke, traumatic brain injury, neuropathic pain and multiple sclerosis. Dr. McBurney's former academic positions include: Benjamin Meaker Visiting Industrial Professor in the Medical School at Bristol University (UK); Assistant Director of the Medical Research Council?s Neuroendocrinology Unit (UK); Reader in Neurobiology at the Medical School of the University of Newcastle-upon-Tyne (UK); Visiting Associate in Neurophysiology at the National Institutes of Health (USA); and, Florey Fellow of the Royal Society in Sir Alan Hodgkin's laboratory at Cambridge University (UK). He was awarded a BSc with first-class honours and a PhD from the University of New South Wales, Australia.
Back to 2006 PresentationsHarihara M. Mehendale, Ph.D.
Professor and Kitty DeGree Chair in Toxicology
Director, Training Program in Toxicology
Department of Toxicology, College of Pharmacy
The University of Louisiana at Monroe (ULM)
Dr. Mehendale received his M.S. and Ph.D. degrees from the Toxicology Program at North Carolina State University. He received his postdoctoral training at the University of Kentucky and at the National Institute of Environmental Health Sciences (NIEHS), before joining NIEHS as a Staff Fellow. In 1975, he joined the University of Mississippi Medical Center as Assistant Professor, rose through the academic ranks to full Professor in 1980. He joined the University of Louisiana at Monroe (ULM) in 1992. His research interests span across pulmonary, hepatic, renal and general toxicology of medicinal, industrial and environmental chemicals. His current area of research emphasis involves understanding the role of tissue repair in the ultimate outcome of tissue injury, the mechanisms in control of cell division and tissue repair as well as the molecular events keying these mechanisms. Current research is focused on the impact of age, diabetes, and diet restriction on toxic effects, mechanisms of progression and regression of injuries, and potential adverse health effects of exposure to combinations of chemicals. He has authored over 275 original research and review articles, as well as book chapters. Dr. Mehendale has received several Honors and Awards for his research and scholarly contributions. In 1988, he received the "Burroughs Wellcome Scholar in Toxicology" award given by the Society of Toxicology, U.S.A. In 1993, he received the Zeneca International Travel Award. In 1995, he was named outstanding researcher at ULM and received the "Researcher of the Year" Award. In 1996, the American Association for the Advancement of Science (AAAS) elected him "Science Fellow". In 1999, he received the Best Paper Award for best paper published in Toxicology and Applied Pharmacology. In 2001, received the Society of Toxicology?s Education Award for his eminent contributions to education in toxicology.
Back to 2006 PresentationsLance R. Pohl, Pharm.D., Ph.D.
Section of Molecular and Cellular Toxicology, NHLBI, NIH, Bethesda, MD
Dr. Lance Pohl is the Chief of the Molecular and Cellular Toxicology Section of the Laboratory of Molecular Immunology in the National Heart, Lung, and Blood Institute of the NIH. He received his B.A. in microbiology from the University of California, Berkeley, and Pharm.D. and Ph.D. in medicinal chemistry from the University of California Medical Center, San Francisco. Current studies deal with the role of cytokines and other regulatory factors in modulating the susceptibility of patients to drug-induced liver diseases that are mediated by reactive metabolites and cells of the innate and adaptive immune systems. Genomic, proteomic, and bioinformatic methods are used to discover the susceptibility factors and transgenic animal models are developed to elucidate the molecular and cellular activities of the factors.
Back to 2006 PresentationsDonald G. Robertson, Ph.D., DABT
Dr. Robertson received a BA in biology from The King?s College (NY) as well as a Master?s degree in Environmental Health Sciences and a Ph.D. in Toxicology from the University of Michigan where he subsequently was appointed as a post-doctoral fellow. He is a diplomate of the American Board of Toxicology and past-president of the Michigan Society of Toxicology. He joined Pfizer (then Parke-Davis) in 1986 and currently holds the title of Director and Research Fellow in World-Wide Safety Sciences. Within Safety Sciences, he has served as Director of the Biochemical Toxicology Laboratory and Director of Anti-inflammatory Drug Development. His growing involvement in metabonomic sciences led to his full-time appointment as the Safety Sciences Leader of the Metabonomic Evaluation Group in 2003. He is a charter member of the COMET metabonomic consortium and was the first chair of the toxicology-working group of that consortium. His expertise in metabonomic technology led to various appointments to both industrial and regulatory groups interested in utilizing and understanding this emerging technology. He currently chairs the Biology Context Committee of the Metabolomics Standardization Effort. He serves on the editorial board of Cardiovascular Toxicology and is an ad hoc reviewer for numerous toxicology-oriented journals. He was senior editor of the volume entitled ?Metabonomics in Toxicity Assessment? published in 2005 and has written and presented extensively on the topics of metabonomics and drug-induced toxicity.
Back to 2006 PresentationsDon was educated at the Virginia Polytechnical Institute (B.S., 1980) and the Medical College of Virginia at Richmond (M.D., 1984), after which he served as an internal medical resident at the University of California at San Francisco (1984-8). He followed with a fellowship in gastroenterology at UCSF (1988-92), and was chosen for staff positions there as a clinical instructor and attending physician (1992-5), assistant professor of medicine (1995-6). He then moved to Duke University as associate professor of medicine and Director of Hepatology at the Duke Liver Center (1997-2002). He was promoted to professor of medicine at Duke (2002-5), and then moved to the University of Texas Southwestern at Dallas TX as Professor of Medicine and Director, Digestive Diseases and Liver Division in late 2005.
During this time he received many awards (summa cum laude 1980; A.H. Strauss award for academic excellence, 1982; Alpha Omega Alpha, 1983; A.D. Williams award for being top student in junior clerkship and the Merck award for academic excellence, 1983; the William Branch award as top student in internal medicine and Herman Hertzberg award for excellence in service and scholarship, 1984; the American Gastroenterological Association senior fellow award, 1990, and its industry award, 1992; the World Congress of Gastroenterology young scholar award, 1994; Glaxo Institute of Digestive Health research award, 1995; Miles and Shirley Fiterman basic researcg award 1996; Burroughs Wellcome clinical scientist research award, 2000; and was elected to the American Society of Clinical Investigation, 2001.
Back to 2006 PresentationsJames E. Sanders, DVM, PhD
Diplomate of the American Board of Toxicology, Preclinical Development Team Leader, CDDD, PRDUS
Dr. James. E. Sanders joined J&J PRD in 2005 as a Preclinical Development Team Leader. In addition to preclinical development, he represents his company externally in forums and working parties such as the ILSI, Toxicology Forum, and PhRMA. His career in nonclinical safety assessment of pharmaceuticals spans over 25 years. Previously he was employed at Rh?ne-Poulenc Rorer as Director of Toxicology in 1987 and had continued with the merged companies, Aventis and Sanofi-Aventis, as a Distinguished Scientist. He was previously employed from 1981 to 1987 as a pathologist at Merck, Sharp and Dohme and from 1978 to 1981 as a staff pathologist in the U.S. Army at Walter Reed Army Institute of Research. Jim attended Ohio State University where he gained a DVM, an MS in Pharmacology and a PhD in toxicology. He is certified by the American Board of Toxicology and is a member of the Society of Toxicology, Teratology Society, DIA, and AVMA.
Back to 2006 PresentationsBorn in South Africa, Dr. Seeff graduated from the Medical School of the University of the Witwatersrand, Johannesburg, in 1961. He came to the United States in late 1964 to work with Dr. Hyman J. Zimmerman, then Chief of the Department of Medicine, Mount Sinai Hospital, Chicago, Illinois and Chairman of the Department of Medicine, Mount Sinai Medical School. Dr. Zimmerman, one of the founders of the discipline of Hepatology, was a revered teacher, mentor, administrator and clinical researcher, and also this country?s leading expert in the area of hepatotoxicity.
In 1965, he moved with Dr. Zimmerman to Washington DC to complete his training in Internal Medicine at the VA Medical Center and to pursue a career in Hepatology. While there, he initiated what was to be the first of four large-scale VA Cooperative studies related to viral hepatitis, types B and what was then called, non-A, non-B. In 1968, he moved again with Dr. Zimmerman to the VA Medical Center, Boston, Massachusetts, where he assumed the position of Chief of Liver Disease and continued overseeing the Cooperative Studies. In 1971, he returned to the VA Medical Center in Washington DC as Assistant Chief of Medicine for a period of 8 years. During this time, continuing as the PI for the 4 Cooperative Studies, he extended his interest in research in viral hepatitis and established a research hepatitis testing laboratory. In 1979, he was appointed Chief of Gastroenterology, Hepatology and Nutrition at that hospital, a position he held until 1998. During this time, he established a GI/Hepatology training program that involved Georgetown University and the GI Section of the National Institutes of Health. He became Professor of Medicine at Georgetown University in 1984.During this period, Dr. Seeff continued to study viral hepatitis, conducting a number of long-term natural history studies of both hepatitis B and C. These studies were funded by the VA, the National Cancer Institute, the National Heart, Lung and Blood Institute and the National Institute of Allergy and Infectious Diseases. He also worked with Dr. Zimmerman on issues of hepatotoxicity. He is a long-standing member of the American Association for the Study of Liver Diseases, serving on several committees, and was Councilor-at-Large from 1997-2000. He is the senior author of the AASLD Guidelines on Treatment of Hepatitis C and participated in writing AASLD Guidelines regarding laboratory tests to screen, diagnose and monitor liver disease.
In 1998, he moved to the National Institute of Diabetes and Digestive and Kidney Diseases, NIH in the position of Senior Scientist for Hepatitis Research, a position he still holds, now in the Liver Disease Research Branch. This position has involved developing and overseeing numerous clinical research trials and networks, organizing several workshops (Complementary and Alternative Medicine for Chronic Liver Disease, the 1997 and 2002 Consensus Development Conference on Hepatitis C, Hepatitis C and Renal Disease, Hepatitis C in Incarcerated Persons, Hepatocellular Carcinoma, etc.), and coordinating activities related to hepatitis among several Government Agencies (NIH, VA, Centers for Disease Control, Department of Defense, Bureau of Prisons). Currently, he is deeply involved with a number of NIDDK-supported multicenter trials including the Drug-Induced Liver Injury Network (DILIN) Study.
John R. Senior, M.D.
Associate Director for Science, Office of Pharmacoepidemiology and Statistical ScienceFood and Drug Administration
John Senior was educated in chemical engineering at Drexel University, in physics at the Pennsylvania State University, and medicine at the University of Pennsylvania. After internal medicine residency program and a clinical fellowship in gastroenterology at the Hospital of the University of Pennsylvania, he worked on the mechanisms of intestinal absorption of fats across the small intestinal epithelial cells into the lymph and blood at the Massachusetts General Hospital and Harvard University. Returning to Penn, he established a Gastrointestinal Research Laboratory at the Philadelphia General Hospital (PGH), and there worked on detecting viral hepatitis after transfusion of blood. That hospital was the first in the world to screen all donor blood for the marker ("Australia antigen") of hepatitis B. He was elected to the council of the American Association for the Study of Liver Diseases, and was its 24th President in 1973-4.
On sabbatical from PGH, he investigated the possibilities of computer simulation of patients for purposes of testing candidates for certification of medical competence by the American Board of Internal Medicine, and developed the first models of tests that are currently are in use as the Computer-Based Examination. At the Graduate Hospital he directed its Clinical Research Center and later opened a Special Treatment Unit for Alcohol-Related Disorders at Graduate Hospital that provided advanced medical care for over 3500 patients admitted with life-threatening medical complications of alcohol abuse, referred from the Philadelphia area.
He then worked in corporate pharmaceutical research and development, at Squibb as Director of Regulatory Projects (1979-81), at Sterling-Winthrop Research Institute as Vice President for Worldwide Clinical Affairs (1981-4), and as an independent consultant to numerous pharmaceutical companies in Japan, Europe, and North America (1984-95). In June 1995 he joined the Center for Drug Evaluation and Research of the Food and Drug Administration as a medical reviewer for gastrointestinal drug products, in January 2000 as Senior Scientific Advisor to the Director of the Office of Drug Safety, consulting on drug-associated liver problems to the reviewing divisions and conducting research on detecting and attributing causality for idiosyncratic drug-induced liver injury, and July 2003 as Associate Director for Science, Office of Pharmacoepidemiology and Statistical Sciences, and is the principal hepatology consultant for the FDA.
Dr. Thomas is currently a Research Advisor in the Department of Investigative Toxicology at Lilly Research Laboratories, a division of Eli Lilly & Co., in Indianapolis, IN. He received his B.S. and M.S. degrees in Veterinary Science at Penn State and his Ph.D. in 1986 in Biochemistry and Environmental Toxicology from Michigan State University. Craig was then granted an NIEHS Research Service Award to conduct postdoctoral work at Oregon State where he investigated mechanisms of calcium-dependent hepatocellular injury. From 1980-1996 his academic and pharma industry research efforts focused on the role of free radicals in toxicity and disease, and in the development of pharmaceutical antioxidants. In January 2000, Craig joined the Lilly Development Centre in Brussels, Belgium as Head of Investigative Toxicology and Toxicology Projects. It was here that he began his studies on the use of high field NMR as a tool to study metabolic perturbations induced by xenobiotics. Following his return to the United States in the summer of 2002 he continues to work on the development of metabonomics as an enabling technology to revolutionize clinical and pre-clinical drug development. Dr. Thomas is a member of the Society of Toxicology, and has authored 43 peer reviewed journal articles, 25 invited review articles, holds 4 US patents and is the Co-Editor of the book ?Oxygen Radicals and the Disease Process.?
Jack Uetrecht received his Ph.D. in Organic Chemistry from Cornell University in 1972, an M.D. from Ohio State University of 1975 and, after a medical residency, a Clinical Pharmacology Fellowship at Vanderbilt University under the supervision of John Oates in 1981.
Professional Experience: Presently he is a Professor of Pharmacy and Medicine and Canada Research Chair in Adverse Drug Reactions at the University of Toronto. Previously he was the Associate Dean of Pharmacy (1994-1998) and Associate Professor of Pharmacy and Medicine University of Toronto (1985-1993); Assistant Professor of Pharmacology and Medicine, Vanderbilt University (1981-1985).
Research Interests: Mechanisms of idiosyncratic drug reactions with a focus on involvement of the immune system, reactive metabolites and the use of animal models with an extension to human idiosyncratic drug reactions.
Professional Societies and Activities: Chair, Pharmaceutical Sciences grant review committee for the Medical Research Council of Canada (1987-1991); Chair, Gordon Conference on Drug Metabolism (2002); Co-chair of new Gordon Conference on Adverse Drug Reactions (2005); Councilor, ISSX (1991-1994); Councilor, International Union of Pharmacology, Drug Metabolism Section (1992-1998);Editorial Boards: Chemical Research in Toxicology (1992-1997), Chemico-Biological Interactions (1992-1997), Drug Metabolism and Disposition (1997-present), Current Drug Metabolism (1999-present); Journal of Immuntoxicology (2003-present)
Paul Watkins is the Verne S. Caviness Distinguished Professor of Medicine and Professor of Pharmacotherapy, and the Director of the General Clinical Research Center at University of North Carolina, Chapel Hill. Dr. Watkins? area of research has been Drug Metabolism and Disposition. He is one of the top 250 most cited authors in the field of Pharmacology for the two decades ending 2004 according to ISIhighlycited.com. He has served on many national committees, including Toxicology I Study Section of the National Institutes of Health and the Committee for the Comparative Toxicity of Naturally Occurring Carcinogens at the National Academy of Sciences
Dr. Watkins? clinical area of interest is Drug-Induced Liver Injury, and he has consulted widely for industry and governmental agencies in this area. He is the current Chair of the Steering Committee for the Drug Induced Liver Injury Network (DILIN) funded by the National Institute for Diabetes Digestive and Kidney Diseases.
Patrick J. Wier, PhD
Vice President for Safety Assessment, GlaxoSmithKline, King of Prussia PA
Dr. Patrick Wier received his PhD from the University of Rochester in 1985. He has been active as a councilor for the Teratology Society 2001-4, and as a lecturer for the Society of Toxicology (2004: Interpreting female reproductive toxicity data). He has worked and published in the field of toxicology, focusing especially on reproductive tract of primate animals. He is now the Vice President for Safety Assessment of the GlaxoSmithKline Company.
Traumatic Brain Injury
